Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Brepocitinib tosylate by Priovant Therapeutics for Intermediate Uveitis: Likelihood of Approval
Brepocitinib tosylate is under clinical development by Priovant Therapeutics and currently in Phase II for Intermediate Uveitis. According to GlobalData,...
Brepocitinib tosylate by Priovant Therapeutics for Posterior Uveitis: Likelihood of Approval
Brepocitinib tosylate is under clinical development by Priovant Therapeutics and currently in Phase II for Posterior Uveitis. According to GlobalData,...
Brepocitinib tosylate by Priovant Therapeutics for Panuveitis: Likelihood of Approval
Brepocitinib tosylate is under clinical development by Priovant Therapeutics and currently in Phase II for Panuveitis. According to GlobalData, Phase...
Brepocitinib tosylate by Priovant Therapeutics for Non-infectious Uveitis: Likelihood of Approval
Brepocitinib tosylate is under clinical development by Priovant Therapeutics and currently in Phase II for Non-infectious Uveitis. According to GlobalData,...
Brepocitinib tosylate by Priovant Therapeutics for Dermatomyositis: Likelihood of Approval
Brepocitinib tosylate is under clinical development by Priovant Therapeutics and currently in Phase III for Dermatomyositis. According to GlobalData, Phase...
Brepocitinib tosylate by Priovant Therapeutics for Hidradenitis Suppurativa: Likelihood of Approval
Brepocitinib tosylate is under clinical development by Priovant Therapeutics and currently in Phase II for Hidradenitis Suppurativa. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Roivant Sciences's Brepocitinib tosylate?
Brepocitinib tosylate is a small molecule commercialized by Roivant Sciences, with a leading Phase III program in Dermatomyositis. According to...
Risk adjusted net present value: What is the current valuation of Roivant Sciences's Brepocitinib tosylate?
Brepocitinib tosylate is a small molecule commercialized by Roivant Sciences, with a leading Phase III program in Dermatomyositis. According to...